Hydroxychloroquine in fighting COVID-19 : What led WHO to suspend clinical trial of drug?

Pacheco, Thyago José Arruda; Souza, Danielle Galdino de; Faria, Raquel Santos; Andrade, Laise Rodrigues de

Registro completo de metadados

Campo DC	Valor	Idioma
dc.contributor.author	Pacheco, Thyago José Arruda	-
dc.contributor.author	Souza, Danielle Galdino de	-
dc.contributor.author	Faria, Raquel Santos	-
dc.contributor.author	Andrade, Laise Rodrigues de	-
dc.date.accessioned	2021-05-10T13:06:18Z	-
dc.date.available	2021-05-10T13:06:18Z	-
dc.date.issued	2020	-
dc.identifier.citation	PACHECO, Thyago José Arruda; SOUZA, Danielle Galdino de; FARIA, Raquel Santos; ANDRADE, Laise Rodrigues de. Hydroxychloroquine in fighting COVID-19: what led WHO to suspend clinical trial of drug?. In: ALVES, Gleica Soyan Barbosa; OLIVEIRA, Eliene de (org.). Tópicos em ciências da saúde. Belo Horizonte: Editora Poisson, 2020. v. 21, cap. 21, p. 158-165. DOI: 10.36229/978-65-5866-037-8. Disponível em: https://www.poisson.com.br/livros/saude/volume21/Saude_vol21.pdf. Acesso em: 30 abr. 2021.	pt_BR
dc.identifier.uri	https://repositorio.unb.br/handle/10482/40848	-
dc.language.iso	Inglês	pt_BR
dc.publisher	Editora Poisson	pt_BR
dc.rights	Acesso Aberto	pt_BR
dc.title	Hydroxychloroquine in fighting COVID-19 : What led WHO to suspend clinical trial of drug?	pt_BR
dc.type	Parte de livro ou capítulo de livro	pt_BR
dc.subject.keyword	Hidroxicloroquina	pt_BR
dc.subject.keyword	Testes	pt_BR
dc.subject.keyword	Covid-19	pt_BR
dc.subject.keyword	SARS-CoV-2	pt_BR
dc.rights.license	Autorização concedida pelo representante legal da Editora Poisson a Universidade de Brasília (UNB), em 23 de abril de 2021, para disponibilizar o capítulo “Hydroxychloroquine in fighting COVID-19: What led WHO to suspend clinical trial of drug?” do livro Tópicos em Ciências da Saúde - Volume 21 no Repositório Institucional da Universidade de Brasília, para uso sem fins comerciais e livre acesso. A cessão é para o Repositório Institucional da Universidade de Brasília é sem ressarcimento de direitos autorais, conforme disposições legais previstas na Lei no 9.610, de 19 de fevereiro de 1998.	pt_BR
dc.identifier.doi	10.36229/978-65-5866-037-8	pt_BR
dc.description.abstract1	Purpose: On March 11, 2020 the pandemic status of COVID-19 (Coronavirus Disease 2019) was declared. The milestone of thousands of daily deaths from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was reached worldwide. So far, there is still no proven effective treatment against this disease. This study summarizes the main clinical findings on the use of hydroxychloroquine (HCQ) to treat COVID-19. The goal is to gather the evidence that led WHO to suspend the HCQ arm of its Solidarity Trial, contributing to the understanding of its denouement. Methods: LitCovid platform was searched for the term "hydroxychloroquine” in the “treatment” field. All clinical studies published in the period from January 1st to June 17th were included in the review. Results: We included ten articles on HCQ in COVID-19 positive patients (eight non-randomized and two randomized clinical studies). Most studies did not report a benefit in the use of HCQ. There is no evidence of decreased risk of intubation or death, and in some cases adverse effects have been reported, such as abnormal liver function, transient blurred vision, diarrhea. Conclusions: The overview of the available data on HCQ in COVID-19 patients can guide future studies, still needed to support public policies and health authorities in fighting COVID-19.	pt_BR
dc.description.unidade	Instituto de Ciências Biológicas (IB)	pt_BR
dc.description.unidade	Departamento de Genética e Morfologia (IB GEM)	pt_BR
Aparece nas coleções:	Livros e afins UnB - Covid-19